Merck's COVID-19 pill cuts risk of death, hospitalization by 50% - study

If authorized, molnupiravir, which is designed to introduce errors into the genetic code of the virus, would be the first oral antiviral medication for COVID-19.

An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021.

(photo credit: MERCK & CO INC/HANDOUT VIA REUTERS)

ByREUTERS

OCTOBER 1, 2021 13:19

Merck's COVID-19 pill cuts risk of death, hospitalization by 50% - study

If authorized, molnupiravir, which is designed to introduce errors into the genetic code of the virus, would be the first oral antiviral medication for COVID-19.

Driving innovation at the frontiers of genomic medicine

The healthy combination that will protect you this winter

Merck's COVID-19 pill cuts risk of death, hospitalization by 50% - study

If authorized, molnupiravir, which is designed to introduce errors into the genetic code of the virus, would be the first oral antiviral medication for COVID-19.

See more on